WELCOME TO THE GLOBAL HEPATITIS SUMMIT!
The continuum of research from basic science to clinical science and public health applications
It is with great pleasure that we invite you to join us at The Westin Bonaventure Hotel & Suites, Los Angeles, US March 18 – 21, 2025 for the 19th Global Hepatitis Summit (GHS 2025), a 50-year legacy of the International Symposium on Viral Hepatitis and Liver Disease (ISVHLD).
It will be our pleasure to welcome you to Los Angeles for this historic scientific meeting.
The Global Hepatitis Summit 2025 will proceed as planned in Los Angeles, despite the recent fires. The event will be held at The Westin Bonaventure Hotel & Suites from March 18 to 21, 2025. The organizers are committed to ensuring a safe and successful summit for all attendees.
Norah Terrault
Global Hepatitis Summit 2025
Co-Chair
John Ward
Global Hepatitis Summit 2025
Co-Chair
Harry Janssen
International Advisory Committee
Chair
The North American Viral Hepatitis Elimination Summit, a collaboration of the American Association for the Study of the Liver (AASLD), Canadian Association for the Study of the Liver (CASL), and Mexican Association of Hepatology (AMH) will be delivered on Tuesday March 18th, 2025, at the Global Hepatitis Summit in Los Angeles.
WHAT TO EXPECT: INNOVATION IN LIVER DISEASE
Online
learning
Scientific &
networking
program
Industry
symposia and
exhibition
OUR 3-TIER APPROACH
Basic-Translational Science
- HCV/flavivirus virology
- HCV/flavivirus immunology
- HBV/HDV virology
- HBV/HDV immunology
- Preclinical therapeutics HBV/HDV
- Hepatocellular carcinoma
- Other viruses (including HEV)
- Liver inflammation and fibrogenesis
- Liver pathogen detection and discovery
Clinical Science
- HCV screening, clinical care delivery and outcomes
- HBV screening, clinical care delivery and outcomes
- Approved HBV treatments
- New and promising HBV therapies (Phase 2 and beyond) and diagnostics
- Approved and promising new HDV therapies and diagnostics
- Viral hepatitis coinfections and morbidities: HIV, MASLD/MASH
- Hepatocellular carcinoma clinical
- Hepatocellular carcinoma treatment
- Biomarkers for liver diseases
- Other viruses, clinical and treatment
Public Health
- Prevention of new infections, including vaccination and injection safety
- Epidemiology of HCV
- Epidemiology of HBV/HDV
- Epidemiology of hepatocellular carcinoma
- HBV elimination: achievements and challenges
- HCV elimination: achievements and challenges
- Simplified community and clinic- based approaches to viral hepatitis care cascade
- Strategies for equitable service delivery to overcome disparities in viral hepatitis
ENDORSING SOCIETIES
MEET THE EXPERTS
Sanjeev Arora
Director, Project ECHO, and Professor of Medicine, UNM Health Sciences Center
Boatemaa Ntiri-Reid
Senior Director, Syndemic Approaches, NASTAD
Carolyn Wester
Director of the Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, U.S. CDC
Elmar Jaeckel
Medical Director, Toronto Liver Transplant Program, Ajmera Transplant Centre University Health Network
Javier GarcÃa-Samaniego
Assistant Physician in the Digestive System Service of the Carlos III Hospital in Madrid
Jennifer Flemming
Associate Professor, Queen's University
Andrea Cox
Professor of Medicine, Oncology, and Immunology, The Johns Hopkins University School of Medicine
Ben Cowie
Director, WHO Collaborating Centre for Viral Hepatitis
Christine Greenway
Infectious disease physician and clinician researcher, Jewish General Hospital, McGill University
Alain H Litwin
Professor, Clemson University School of Health Research
Bernadette Lettner
Ontario Hepatitis C Elimination Lead: Clinical Training, Guidance and Monitoring, UHN
Risha Irvin
Health Equity Program Director, Johns Hopkins Health System
Fatima Higuera
Head of Gastroenterology and Hepatology, Mexico's General Hospital "Dr. Eduardo Liceaga"
Mia Biondi
Assistant Professor at York University
Kimberly Page
Professor, University of New Mexico Health Sciences Center
Robert Gish
Principal, Robert G Gish Consultants LLC
Carla Coffin
Professor Cumming School of Medicine University of Calgary
Andrew Aronsohn
Associate Professor of Medicine, University of Chicago
Aldo Torre Delgadillo
Mexican Association of Hepatology
Ralf Bartenschlager
Director of the Department of Molecular Virology, Centre for Infectious Diseases at the Medical Faculty of the University of Heidelberg
Edward Gane
Professor of Medicine
John Ward
Director of the Coalition for Global Hepatitis Elimination of the Task Force for Global Health
Thor Dantas
Medical Doctor Professor, Federal University of Acre
Tawasek Tanwandee
Professor, Siriraj Hospital/Mahidol University
Su Wang
Medical Director, Viral Hepatitis Programs & Center for Asian Health | Global Advisor, Cooperman Barnabas Medical Center, RWJBH| Hepatitis B Foundation
Sione Crawford
CEO, Harm Reduction Victoria
Saeed Hamid
Professor of Medicine, Director Clinical Trials Unit, Aga Khan University
Ponsiano Ocama
Professor, Makerere University College of Health Sciences
Nicole Kim
Assistant Professor, University of Washington
Neil Mehta
Professor of Medicine, University of California, San Francisco (UCSF)
Nathan Furukawa
Senior Advisor for Hepatitis C Elimination, U.S. Centers for Disease Control and Prevention
Nasra Giama
Clinical Associate Professor, Mayo Clinic, University of Minnesota
Meg Doherty
Director Global HIV, Hepatitis and STI Programmes
Margaret Hellard
Deputy Director, Burnet Institute
Lindsey Hiebert-Suwondo
Deputy Director, Coalition for Global Hepatitis Elimination, Task Force for Global Health
Kate Dunn
Assistant Professor, York University
Julie Bruneau
Professor, Université de Montréal
Jennifer Havens
Professor, University of Kentucky
Greg Dore
Professor, Kirby Institute, UNSW
Fabien Zoulim
Professor, Lyon University
Camila Picchio
Post Doctoral Researcher, Barcelona Institute for Global Health (ISGlobal)
Anna Lok
Professor, University of Michigan
Alexander Stockdale
Senior Clinical Lecturer/ Consultant in Infectious Diseases, University of Liverpool
Kosh Agarwal
Consultant Hepatologist, King's College Hospital NHS
Ulrike Protzer
Chair of Virology, Technical University of Munich
Percy Knolle
Director Institute of Molecular Immunology · TU München
Patrick Kennedy
Consultant Hepatologist and Gastroenterologist. Viral hepatitis. Chronic liver disease.
Oluwaseun (Seun) Falade-Nwulia
Assistant Professor of Medicine, Division of Infectious Diseases at the Johns Hopkins University School of Medicine
Maria Buti
Professor, Maria Butà Ferret
Marc Ghany
Senior Investigator, Clinical Hepatology Section, Liver Diseases Branch National, Institutes of Health of United States
Ju Dong Yang
Associate Professor, Cedars Sinai Medical Center
Jennifer Price
Assistant Clinical Professor of Medicine, University of California San Francisco
Jean-Michel Pawlotsky
Professor of Medicine French National Reference Center for Viral Hepatitis B, C and Delta Chief, Department of Biology Head, Department of Virology
Harry Janssen
Professor of Hepatology, Erasmus MC, University Medical Center Rotterdam
Funmi Lesi
Observer, Leader of Hepatitis Division, Global HIV, Hepatitis and STI Programmes, World Health Organization
Andrew Owen
Co-Director of the Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool
Alexander Ploss
Professor, Department of Molecular Biology, Princeton University
Adam Gehring
Scientific Director, Scwhartz Reismand Liver Research Centre
Jordan Feld
Professor of Medicine
50 YEARS OF EXCELLENCE IN THE MAKING: MEET ISVHLD!
Join our global network of hepatologists, nurses, policymakers, patients and partner professionals dedicated to the same cause!
With a person dying every 30 seconds from a hepatitis related illness, the International Symposium on Viral Hepatitis and Liver Disease is dedicated to advancing science, understanding, prevention and elimination of hepatitis worldwide.
Now with a history spanning over 50 years, ISVHLD is a game-changer in mediating enhanced science, advocacy and understanding the pathophysiology of hepatitis.
TESTIMONIALS
EACCME
European Accreditation Council for Continuing Medical Education
The Global Hepatitis Summit 2023, Paris, France, 23/05/2023-28/05/2023 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 24 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
YOUR L.A. STORY IS AWAITING!
“In Los Angeles, everyone is a star.” –Denzel Washington
